Roma 10 maggio 2023
La Biotech Takis in prima linea per lo sviluppo di soluzioni contro patogeni ad alto potenziale epidemico/pandemico.

English version

La Biotech Takis annuncia la realizzazione di un laboratorio innovativo ed altamente specializzato presso il Tecnopolo di Castel Romano per lo studio di patogeni di classe 3 e per la Ricerca di nuove soluzioni terapeutiche.

“Siamo entusiasti per la recente acquisizione dell’innovativo modulo BSL-3, uno strumento di ultima generazione per isolare e manipolare in condizioni di massima sicurezza patogeni pericolosi per l’uomo, come SARS-CoV-2. Questa nuova struttura rappresenta per Takis, per il territorio e per il Paese l’opportunità di raccogliere una sfida più che mai attuale nel nostro tempo: abbracciare un nuovo approccio alla ricerca contro le malattie infettive che tenga conto del rischio di future pandemie.” dichiara Luigi Aurisicchio, CEO/CSO della Takis.

“Dopo aver realizzato un vaccino contro Covid-19 che ha raggiunto con successo la Fase I della sperimentazione clinica, i nostri ricercatori avranno adesso la possibilità di svolgere ricerche sempre più avanzate che aiuteranno a prevenire e ad affrontare possibili pericoli futuri“ continua Emanuele Marra, Chief Operating Officer alla Takis. “Il vaccino COVID-eVax sviluppato alla Takis ha infatti seguito un percorso di sperimentazione che nasce da Castel Romano già a gennaio 2020 ma solo avvalendosi di collaborazioni nazionali ed internazionali, ha potuto dimostrare la sua efficacia contro SARS-CoV-2 in ambiente BSL-3” continua Emanuele Marra, COO della Takis.

“Tramite questo modulo innovativo potremo dunque valutare velocemente e in tutta sicurezza nuove molecole, vaccini o anticorpi monoclonali per il trattamento o la prevenzione di malattie infettive ad alto rischio di diffusione. Ad esempio per SARS-CoV-2 siamo riusciti a sviluppare in pochissimo tempo vaccini specifici e una batteria di potenti anticorpi contro le varianti emergenti del virus. Non solo. In collaborazione con l’Accademia, la Takis è molto attiva sul territorio Laziale per la realizzazione di laboratori condivisi e per la formazione di giovani ricercatori ad elevata specializzazione, di cui oggi l’Italia è ancora carente rispetto ad altri paesi” conclude Giuseppe Roscilli, CTO della Takis.

La BSL-3 rappresenta quindi un importante investimento sulla ricerca italiana e sulla tutela della salute di tutti noi.

Rome 10 May 2023.

Takis biotech is at the forefront of the development of solutions against pathogens with high epidemic/pandemic potential.

Italian version

Takis announces the creation of an innovative and highly specialized laboratory at the Castel Romano Technopole for the study of class 3 pathogens and for the search for new therapeutic solutions.

“We are enthusiastic about the recent acquisition of the innovative BSL-3 module, a latest generation tool for isolating and handling pathogens dangerous to humans, such as SARS-CoV-2, under conditions of maximum safety. This new structure represents for Takis, for the territory and for the country the opportunity to take up a challenge more relevant than ever in our time: to embrace a new approach to research against infectious diseases that takes into account the risk of future pandemics." declares Luigi Aurisicchio, CEO/CSO of Takis.

"After having developed a vaccine against Covid-19 that has successfully reached Phase I clinical trial, our researchers will now have the opportunity to carry out increasingly advanced research that will help prevent and address possible future dangers" continues Emanuele Marra, Chief Operating Officer at Takis.

"The COVID-eVax vaccine was developed at Takis and its experimentation started in Castel Romano as early as January 2020 but only by making use of national and international collaborations, has it been able to demonstrate its effectiveness against SARS-CoV-2 in a BSL- 3” continues Emanuele Marra, COO of Takis.

“Through this innovative module we will therefore be able to quickly and safely evaluate new molecules, vaccines or monoclonal antibodies for the treatment or prevention of infectious diseases with a high risk of spreading. For example, for SARS-CoV-2 we managed to develop specific vaccines and a library of powerful antibodies against the emerging variants of the virus in a very short time. Not only. In collaboration with the Academy, Takis is at the forefront in Lazio for the creation of shared laboratories and for the training of highly specialized young researchers, of which Italy is still lacking today compared to other countries" concludes Giuseppe Roscilli, CTO of Takis.

The BSL-3 therefore represents an important investment in Italian research and in protecting the health of all of us.

COVID-eVax PHASE 1 CLINICAL TRIAL RESULTS PUBLISHED

January 11, 2023 – Takis and Rottapharm Biotech announce the advance publication of the article “A first-in-human trial on the safety and immunogenicity of COVID-eVax, a cellular response-skewed DNA vaccine against COVID-19” by L. Aurisicchio et al in Molecular Therapy, the leading journal for research in the areas of gene transfer, vector development, stem cell manipulation, gene- and cell-based therapeutics, and vaccine development.

COVID-eVax PHASE 1 CLINICAL

COVID-eVax is a DNA vaccine encoding the receptor binding domain (RBD) of the SARS-CoV-2 spike protein. It is the first COVID-19 vaccine based on the DNA platform to reach clinical development in Europe and it was developed in synergy with an innovative technology called "electroporation", which thanks to short electrical stimuli mediates the passage of DNA inside the cells and activates the immune system. Among the important advantages, DNA is cheap, does not need complex formulations and does not need the cold chain.

The study is the result of a fruitful collaboration within a 100% Italian network: the two companies developing COVID-eVax (Takis and Rottapharm Biotech); the leader in the electroporation technology (IGEA); important academic institutions and clinical centers (San Gerardo Hospital in Monza with the University of Milan-Bicocca, the National Cancer Institute IRCCS Pascale in Naples and the Clinical Research Center in Verona); the VisMederi laboratories in Siena, worldwide expert in viral and immune assays.

COVID-eVax was well tolerated and induced an immune response (binding antibodies and/or T cells) in up to 90% of the volunteers at the highest dose. However, the vaccine did not induce neutralizing antibodies, while particularly relevant was the T cell-mediated immunity, with a robust Th1 response. This T cell-skewed immunological response adds significant information to the DNA vaccine platform and should be assessed in further studies for its protective capacity and potential usefulness also in other therapeutic areas, such as Oncology.

Click here to access the online paper on Molecular Therapy

Takis
Takis is a biotechnology company created by a group of scientists formerly from Merck Research Laboratories (MRL) and it is located in Rome (Italy). The group has more than 15 years of experience and proven expertise in drug discovery in Oncology and is recognized for the design and implementation of a number of innovative technologies, including that of DNA gene therapy. One of Takis’s core assets is its experience with electroporation, a technology that can be used for a variety of clinically useful applications, from vaccine development to somatic gene therapy. Takis’ pipeline includes four cancer vaccine candidates based on this technology. Takis is also actively involved in the generation of humanized monoclonal antibodies for use in oncology and infectious diseases, including COVID-19.

Takis contact
Dr. Luigi Aurisicchio (CEO/CSO)
This email address is being protected from spambots. You need JavaScript enabled to view it.

Rottapharm Biotech
Rottapharm Biotech is a research company dedicated to the discovery and development of innovative drugs. It is located in Monza (Italy) The company expertise in research and development includes medicinal / computational chemistry for small molecules, a proprietary platform for the generation and selection of new monoclonal antibodies and the development of other biological drugs and advanced therapies, the validation of new molecular targets, the pharmacological, pharmacokinetic, toxicological and pharmaceutical characterization of new drug candidates; the design and conduct of innovative clinical trials. The company strategy is to develop its own pipeline independently and then seek partnerships with pharmaceutical companies, as well as investing in alliances on innovative projects of other biotech companies or university spin-offs.

Rottapharm Biotech contact
Dr. Federica Girolami (Business Development, Scientific Liaison and Drug Safety Director)
This email address is being protected from spambots. You need JavaScript enabled to view it.

Takis is glad to announce the promotion of Giuseppe Roscilli and Emanuele Marra in their new roles.

Takis biotech

Giuseppe assumes the role of Chief Technical Officer (CTO). His key responsibilities to keep Takis up to date with the times and the continuous evolution of the market will include:

Monitoring of new technologies and evaluation of their potential applied to products or services;
supervision of research projects to ensure they bring added value to society;
the technical assessment of the potential of possible collaborations with other companies or research bodies;
promote and compare the technological level of the company by participating in conferences and fairs and by taking part in associations or confederations or professional groups, etc.

In close collaboration with the CEO/CSO, Giuseppe will therefore have the task of identifying and converting the possibilities offered by technology into strategic decisions for the company.

Emanuele is the Chief Operating Officer (COO), who in close collaboration with the CEO/CSO and with the Administration will deal with the following aspects:

Optimization of the organizational structure, in terms of management effectiveness and efficiency, in order to guarantee the achievement of corporate objectives;
Strategic guidance and definition of investment, development and management plans;
Preparation of the annual and multi-year plan of company activities;
Continuous improvement of internal operating processes;
Enhancement of all the professionals present;
Coordination of corporate functions;
Improvement of the economic-financial aspects, with particular attention to the optimization of internal resources.

Emanuele will also be directly responsible for the BSL-3 laboratory under construction and for the development and application of the in vivo models.

Congratulations to Giuseppe and Emanuele for their continued commitment to business growth!

BIO International Convention

June 13-16, 2022・San Diego Convention Center

Join us in San Diego at #BIO2022 from June 13-16. This year’s conference is back as an in-person event featuring networking, scientific programming, and partnering opportunities. We are presenting our next generation Covid-19 vaccine, personalized cancer vaccines and monoclonal antibodies pipeline.

Contact our CEO, Luigi Aurisicchio at ITA booth to discuss how we can develop our innovative genetic vaccines together or get your therapy to market faster.

Official Site

Takis partner of EIT Health featured in the film: Armed with innovation: The fight to beat the pandemic

Watch the film and get a sense of the incredible work of the research and innovation community in responding to the pandemic and getting us back to a ‘semi-normal’ way of life.

Takis has contributed to fighting the pandemic with its COVID-eVax, an innovative vaccine based on DNA platform.

A COVID-19 spotlight special edition

EIT Health expedited the initiation of activity to support the fight against COVID-19 in the spring of 2020. New products and services were needed including testing and diagnostics, treatments and vaccines, medical and personal protective equipment, clinical support, and patient monitoring. So we launched 15 projects to find and launch new solutions in these areas. Promising European start-ups were also struggling with the economic downturn, so EIT Health launched support to help them weather the storm and continue their vital work. Finally, we launched the ‘making connections’ marketplace which allowed those working in healthcare across the world to connect with others for cooperation opportunities. This COVID-19 special edition tells the story of the actions of the EIT Health community as the pandemic unfolded in an approximately 45-minute film.

Roma 10 maggio 2023La Biotech Takis in prima linea per lo sviluppo di soluzioni contro patogeni ad alto potenziale epidemico/pandemico.

Rome 10 May 2023. Takis biotech is at the forefront of the development of solutions against pathogens with high epidemic/pandemic potential.